Sotyktu is not approved to treat rheumatoid arthritis. Adverse Reactions. The safety of Sotytku was assessed in 2 placebo- and active-controlled studies, PSO-1 and PSO-2, ...

Sotyktu (deucravacitinib) is a brand-name drug that’s prescribed for moderate to severe plaque psoriasis in certain adults. Sotyktu comes as an oral tablet that’s typically taken once per day.

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. "Today ...

Bristol Myers Squibb today announced new three-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. These ...

Sotyktu (deucravacitinib), taken once daily, is the first and only tyrosine kinase 2 (TYK2) inhibitor available for adults with moderate to severe plaque psoriasis.

PRINCETON, N.J., May 16, 2024--New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis ...

Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call ...

Bristol Myers Squibb Co. (BMS) dodged a black-box warning on the label of just-approved Sotyktu (deucravacitinib), but hurdles lie ahead for the first-in-class, oral, allosteric tyrosine kinase 2 ...

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trial. Sotyktu ...

PRINCETON, N.J., February 16, 2025--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis ...